학술논문
Marginal zone lymphoma international prognostic index: a unifying prognostic index for marginal zone lymphomas requiring systemic treatmentResearch in context
Document Type
article
Author
Luca Arcaini; Côme Bommier; Juan Pablo Alderuccio; Michele Merli; Nicole Fabbri; Maria Elena Nizzoli; Matthew J. Maurer; Vittoria Tarantino; Simone Ferrero; Sara Rattotti; Annalisa Talami; Roberta Murru; Arushi Khurana; Raphael Mwangi; Marina Deodato; Emanuele Cencini; Francesca Re; Carlo Visco; Andrew L. Feldman; Brian K. Link; Marcia Torresan Delamain; Michele Spina; Ombretta Annibali; Alessandro Pulsoni; Andrés J.M. Ferreri; Caterina Cecilia Stelitano; Elsa Pennese; Thomas M. Habermann; Luigi Marcheselli; Sunwoo Han; Isildinha M. Reis; Marco Paulli; Izidore S. Lossos; James R. Cerhan; Stefano Luminari
Source
EClinicalMedicine, Vol 72, Iss , Pp 102592- (2024)
Subject
Language
English
ISSN
2589-5370
Abstract
Summary: Background: Marginal zone lymphomas (MZL), comprised of three unique but related subtypes, lack a unifying prognostic score applicable to all the patients in need for systemic chemotherapy and/or immunotherapy. Methods: Patients from the prospective NF10 study (NCT02904577) with newly diagnosed MZL and receiving frontline systemic therapy at diagnosis or after observation were used to train a prognostic model. The primary endpoint was progression-free survival (PFS) from start of treatment. The model was externally validated in a pooled analysis of two independent cohorts from the University of Iowa and Mayo Clinic Molecular Epidemiology Resource and the University of Miami. Findings: We identified 501 eligible patients. After multivariable modeling, lactate dehydrogenase (LDH) above upper normal limit, hemoglobin